Is Glucagon Administration Compatible With FDG PET/MRI?. (15th August 2022)

• Record Type: Journal Article
• Authors: Maucherat, Bruno; Movassaghi, Roshanack; Fleury, Vincent; Le Thiec, Maelle; Geffroy, Delphine; Labbe-Devilliers, Catherine; Rousseau, Caroline
• Is Part Of: Clinical nuclear medicine. Volume 47:Number 8(2022)
• Page Start: 730
• Page End: 731
• Publication Date: 2022-08-15
• Subjects: FDG -- glucagon -- oncology -- peristalsis -- PET/MRI; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004225
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: Digestive peristalsis generates many artifacts that limit the abdominal and pelvic MRI interpretation. Apart from the hypoglycemia treatment in patients with diabetes, glucagon analog is also indicated for the digestive peristalsis reduction to reduce MRI artifacts. However, its use in PET/MRI is not described, given the risk of interaction with the metabolism of FDG. To assess the importance of this interaction on the FDG PET images, we report FDG PET/MRI images obtained with and without glucagon analog injection.